Dr. Robert Allen Vescio, MD

Dr. Vescio practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Vescio's NPI, 1962509216, was assigned on September 20, 2006. Dr. Vescio graduated from UC San Diego School of Medicine in 1986. Dr. Vescio holds California license G063211.

Dr. Vescio's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Vescio's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. Dr. Vescio is also affiliated with Torrance Memorial Medical Center. The medical group on file is Cedars-Sinai Medical Center. Dmand AI also links Dr. Vescio to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Vescio practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Vescio's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Vescio is board certified in internal medicine by the American Board of Internal Medicine. Dr. Vescio is licensed in California.

Dmand AI lists chronic anemia, immune deficiency disease, lung cancer, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Vescio treats.

CMS data shows 49,387 Medicare services from Dr. Vescio across 20 procedure codes in 2024, for 424 Medicare patients. Medicare paid $1,986,766 for them.

CMS counts 424 Medicare patients who saw Dr. Vescio in 2024. The largest group is 65 to 74, with 191 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 20% are also on Medicaid. Their average risk score is 3.28, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Vescio's median patient age at 73, with 44% women.

In 2024, Dr. Vescio wrote 1,866 Medicare Part D claims for 214 patients. 65% of them were for generic drugs. CMS names the drug for 1,529 of them, across 40 drugs with 11 or more claims each, at $11,836,187 in total drug cost. In 2023, CMS named 1,409 claims across 34 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Vescio for performance year 2024, reported as part of a group. Dr. Vescio accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Vescio as offering telehealth.

Dmand AI links 8 papers to Dr. Vescio, published from 2011 to 2021. 2014 was the busiest year, with 2. Dr. Vescio's most frequent co-authors are Sagar Lonial, MD, James Richard Berenson, MD and Alberto Bessudo, MD.

Dmand AI links Dr. Vescio to 1 clinical trial. Conditions studied include Multiple Myeloma and Blood Protein Disorders.

CMS Open Payments shows 1,621 general payments to Dr. Vescio from 18 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 76% of the total. Celgene Corporation paid the most, $531,511. It also lists 5 research payments totaling $6,544 from 2019 to 2025.

Dmand AI lists 6 awards for Dr. Vescio, most recently America's Top Doctors in 2014.

Dr. Vescio graduated from UC San Diego School of Medicine in 1986.

Dr. Vescio is in network with 7 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.